ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2024
Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021-September 2023.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Novel Fluorescence Polarization Binding Assay for the Main Protease (MACS pharmacology & translational science · 2025Article
- Structural insights into the nirmatrelvir-resistant SARS-CoV-2 MRSC medicinal chemistry · 2025Article
- Real-World Effectiveness of Nirmatrelvir/Ritonavir in Hospitalized Older Adults with Severe Omicron COVID-19: A Retrospective Cohort Study from China.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In response to the COVID-19 pandemic, a new oral antiviral called nirmatrelvir-ritonavir (Paxlovid Objectives: To survey the prevalence, relevance and temporal patterns of M Methods: A total of 93,082 M Results: A declining trend was observed in non-synonymous mutations of M Conclusion: The observations suggest that, as of September 2023, no significant or widespread resistance to nirmatrelvir has developed among SARS-CoV-2 Omicron variants in Ontario. This study highlights the importance of creating automated monitoring systems to track the emergence of nirmatrelvir-resistant mutations within the SARS-CoV-2 virus, utilizing genomic data generated in real-time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.